In this cohort study of insulin users with type 1 diabetes in Colorado, we found that state legislation capping out-of-pocket costs at $100 per prescription for a 30-day supply of insulin was associated with declines in out-of-pocket spend and increases in adherence to insulin therapy. The gene discussed is INS; the disease is type 1 diabetes mellitus.